KRAS and non-small cell lung carcinoma: However, mutant KRAS has been considered undruggable due to the picomolar affinity of RAS for GTP, high intracellular levels of GTP, and the lack of deep binding pockets within RAS proteins to design small molecule inhibitors.[34, 35] Although two KRASG12C inhibitors, Sotorasib and Adagrasib, have been FDA‐approved to treat NSCLC with KRASG12C mutations,[36, 37, 38, 39] which is detectable only in 1–3% of all PDACs.